186 related articles for article (PubMed ID: 34383102)
1. Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.
Karimi M; Zarei T; Bahmanimehr A; Aramesh A; Daryanoush S; Haghpanah S
Ann Hematol; 2021 Dec; 100(12):2901-2907. PubMed ID: 34383102
[TBL] [Abstract][Full Text] [Related]
2. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
3. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Karimi M; Haghpanah S; Farhadi A; Yavarian M
Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
[TBL] [Abstract][Full Text] [Related]
4. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
5. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Banan M; Bayat H; Azarkeivan A; Mohammadparast S; Kamali K; Farashi S; Bayat N; Khani MH; Neishabury M; Najmabadi H
Hemoglobin; 2012; 36(4):371-80. PubMed ID: 22686296
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
Jain M; Chakrabarti P; Dolai TK; Ghosh P; Mandal PK; Baul SN; De R
Blood Cells Mol Dis; 2021 May; 88():102544. PubMed ID: 33610115
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
Ansari SH; Shamsi TS; Siddiqui FJ; Irfan M; Perveen K; Farzana T; Panjwani VK; Yousuf A; Mehboob T
J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
[TBL] [Abstract][Full Text] [Related]
8. Effect of the Hydoxyurea in Yemeni Transfusion-Dependent β-Thalassemia Patients.
Al-Nood HA; Al-Nood RM; Ghanem NS; Al-Hadi AM
Hemoglobin; 2020 Mar; 44(2):104-108. PubMed ID: 32308066
[TBL] [Abstract][Full Text] [Related]
9. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
Bhurani D; Kapoor J; Yadav N; Khushoo V; Agrawal N; Ahmed R; Arora JS; Mehta P
Ann Hematol; 2021 Jun; 100(6):1417-1427. PubMed ID: 33811502
[TBL] [Abstract][Full Text] [Related]
10. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
11. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.
Karimi M; Darzi H; Yavarian M
J Pediatr Hematol Oncol; 2005 Jul; 27(7):380-5. PubMed ID: 16012328
[TBL] [Abstract][Full Text] [Related]
12. Association of Exon 14 of the
Mohammadi Z; Mohammadi R; Haghpanah S; Moghadam M; Pazhoomand R; Karimi M
Hemoglobin; 2020 Nov; 44(6):406-410. PubMed ID: 33164584
[TBL] [Abstract][Full Text] [Related]
13. Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the
Ghosh D; Panja A; Saha D; Banerjee U; Datta AK; Basu A
Genet Test Mol Biomarkers; 2021 Aug; 25(8):563-570. PubMed ID: 34406845
[No Abstract] [Full Text] [Related]
14. Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.
Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):116-125. PubMed ID: 28408107
[TBL] [Abstract][Full Text] [Related]
15. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea therapy in 49 patients with major beta-thalassemia.
Zamani F; Shakeri R; Eslami SM; Razavi SM; Basi A
Arch Iran Med; 2009 May; 12(3):295-7. PubMed ID: 19400608
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis.
Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
Pediatr Hematol Oncol; 2017 Nov; 34(8):435-448. PubMed ID: 29337597
[TBL] [Abstract][Full Text] [Related]
19. The effect and side effect of hydroxyurea therapy on patients with β-thalassemia: a systematic review to December 2012.
Kosaryan M; Zafari M; Alipur A; Hedayatizadeh-Omran A
Hemoglobin; 2014; 38(4):262-71. PubMed ID: 25023087
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]